摘要
为了评估PCC0104007作为精神分裂症治疗剂的潜力,采用MK-801和5-HTP诱导的大鼠模型进行体内药效学研究。结果表明,PCC0104007可减轻MK-801诱导的大鼠高自发活动。PCC0104007可显著抑制5-HTP诱导的甩头反应。在NOR试验和MWM试验中PCC0104007显著改善了MK-801慢性给药引起的认知症状。Golgi染色结果表明,PCC0104007可显著缓解MK-801造成的mushroom树突棘密度降低。认知能力的提高可以通过增加蘑菇棘的数量来实现。PCC0104007与一线抗精神病药物阿立哌唑相比非劣势,是精神分裂症新的候选药物。
To assess the potentiality of PCC0104007 as Schizophrenia treatment,MK-801 and 5-HTP induced rat models are used to study the pharmacodynamics in vivo.The results show that PCC0104007 can alleviate MK-801-induced hyperactivity in rats in open filed test,and can significantly inhibit 5-HTP induced head twitch response,and moreover,it improvs the cognitive impairment induced by sub-chronic administration of MK-801 in NOR test and MWM test.Golgi staining shows that PCC0104007 significantly alleviats the reduction of mushroom spine induced by MK-801.The improvement of cognition might achieve by increment of mushroom spines.As a new candidate for schizophrenia,PCC0104007 shows similar efficacy to aripiprazole in rat model of schizophrenia.
作者
岳馨
刘如梦
朱晓音
田京伟
YUE Xin;LIU Ru-meng;ZHU Xiao-yin;TIAN Jing-wei(School of Pharmacy,Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong,Yantai University,Yantai 264005,China)
出处
《烟台大学学报（自然科学与工程版）》
CAS
2021年第1期42-47,共6页
Journal of Yantai University(Natural Science and Engineering Edition)
基金
国家自然科学基金资助项目(81473188)
山东省重点项目(2017GSF218106)
泰山产业领军人才计划和中国科技部重大新药创制专项(2018ZX09303015)。
作者简介
通信作者:田京伟(ytupharmlab@163.com),教授,博士,主要研究方向为药理学。
